The Effect of Gene Polymorphism on Ticagrelor Metabolism: an Study of 22 CYP3A4 Variants in Chinese Han Population

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2024 Sep 30

PMID 39346054

Authors

Xiaoxia Hu

Peng Wang

Dali Zeng

Guo-Xin Hu

Affiliations

Soon will be listed here.

Abstract

Background: Ticagrelor is a novel oral antiplatelet agent which can selectively inhibit P2Y12 receptor. Bleeding and dyspnea are common adverse reactions of ticagrelor in clinic. The side effects of ticagrelor are correlated with the plasma concentration of ticagrelor.

Objective: This study aimed to evaluate the catalytic characteristics of 22 CYP3A4 alleles identified in the Chinese Han population on the metabolism of ticagrelor , focusing on the effect of CYP3A4 polymorphism on ticagrelor metabolism.

Methods: In this study, insect cells were used to express 22 CYP3A4 variants, which were then incubated with 1-50 µM ticagrelor at 37 °C for 30 minutes to obtain the metabolite (AR-C124910XX). AR-C124910XX was detected by UHPLC-MS/MS to calculate the kinetic parameters, including Km, Vmax and CLint.

Results: Compared to the wild-type, most CYP3A4 alleles exhibited significant differences in intrinsic clearance. The intrinsic clearance of CYP3A4*11, *18 and *33 was much higher than that of wild-type; four variants exhibited similar intrinsic clearance values as the wild-type enzyme; The remaining 14 variants showed significantly reduced intrinsic clearance values, ranging from 1.48% to 75.11% of the wild-type; CYP3A4*30 displayed weak or no activity.

Conclusion: This study conducted a comprehensive assessment of the effect of CYP3A4 variants on ticagrelor's metabolism. The results suggested that there is allele-specific activity towards ticagrelor . These findings can provide some insights and predictions for treatment strategies and risk assessments associated with ticagrelor in clinical practice.

References

Tang P, Zheng X, Hu X, Yang C, Chen Z, Qian J . Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism. Drug Des Devel Ther. 2020; 14:5129-5141. PMC: 7699448. DOI: 10.2147/DDDT.S268796. View

Dai D, Tang J, Rose R, Hodgson E, Bienstock R, Mohrenweiser H . Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001; 299(3):825-31. View

Kabil M, Abo Dena A, El-Sherbiny I . Ticagrelor. Profiles Drug Subst Excip Relat Methodol. 2022; 47:91-111. DOI: 10.1016/bs.podrm.2021.10.003. View

Baxter S, Teft W, Choi Y, Winquist E, Kim R . Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22. Breast Cancer Res Treat. 2014; 145(2):419-28. DOI: 10.1007/s10549-014-2963-1. View

Kang Y, Park S, Yim C, Kwak H, Gajendrarao P, Krishnamoorthy N . The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther. 2008; 85(3):312-8. DOI: 10.1038/clpt.2008.215. View

Teng R . Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clin Pharmacokinet. 2015; 54(11):1125-38. PMC: 4621714. DOI: 10.1007/s40262-015-0290-2. View

Wang J, Zhang H, Wang R, Cai Y . Pharmacokinetics, Bioequivalence and Safety Evaluation of Two Ticagrelor Tablets Under Fasting and Fed Conditions in Healthy Chinese Subjects. Drug Des Devel Ther. 2021; 15:1181-1193. PMC: 7979338. DOI: 10.2147/DDDT.S297918. View

Wang C, Zhao Q, Guo B, Hao J, Zhao J, Ren J . The Plasma Concentration of Ticagrelor and Aspirin as a Predictor of Bleeding Complications in Chinese Acute Coronary Syndrome Patients With Dual Antiplatelet Therapy: A Prospective Observational Study. J Cardiovasc Pharmacol. 2023; 82(2):148-156. DOI: 10.1097/FJC.0000000000001442. View

Bonaca M, Bhatt D, Cohen M, Steg P, Storey R, Jensen E . Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372(19):1791-800. DOI: 10.1056/NEJMoa1500857. View

10.

Liu Q, Ou-Yang Q, Lin Q, Lu X, Ma Y, Li Y . Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro. Fundam Clin Pharmacol. 2021; 36(1):150-159. DOI: 10.1111/fcp.12693. View

11.

Holmberg M, Tornio A, Paile-Hyvarinen M, Tarkiainen E, Neuvonen M, Neuvonen P . CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel. Clin Pharmacol Ther. 2018; 105(2):448-457. DOI: 10.1002/cpt.1177. View

12.

Zhang M, You X, Ke M, Jiao Z, Wu H, Huang P . Prediction of Ticagrelor and its Active Metabolite in Liver Cirrhosis Populations Using a Physiologically Based Pharmacokinetic Model Involving Pharmacodynamics. J Pharm Sci. 2019; 108(8):2781-2790. DOI: 10.1016/j.xphs.2019.03.028. View

13.

Xu R, Wen J, Tang P, Wang C, Xie S, Zhang B . Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro. Basic Clin Pharmacol Toxicol. 2017; 122(4):383-387. DOI: 10.1111/bcpt.12934. View

14.

Jin T, Yang H, Zhang J, Yunus Z, Sun Q, Geng T . Polymorphisms and phenotypic analysis of cytochrome P450 3A4 in the Uygur population in northwest China. Int J Clin Exp Pathol. 2015; 8(6):7083-91. PMC: 4525935. View

15.

Sata F, Sapone A, Elizondo G, Stocker P, Miller V, Zheng W . CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther. 2000; 67(1):48-56. DOI: 10.1067/mcp.2000.104391. View

16.

Schupke S, Neumann F, Menichelli M, Mayer K, Bernlochner I, Wohrle J . Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019; 381(16):1524-1534. DOI: 10.1056/NEJMoa1908973. View

17.

Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A . Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos. 2011; 40(1):83-92. DOI: 10.1124/dmd.111.042259. View

18.

van Eerden R, IJzerman N, Van Meekeren M, Oomen-de Hoop E, Guchelaar N, Visser A . CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients. Clin Pharmacokinet. 2023; 62(8):1129-1139. PMC: 10386914. DOI: 10.1007/s40262-023-01260-4. View

19.

Khalil J, Dimofte T, Roberts T, Keith M, Amaradasa K, Hindle M . Ticagrelor inverse agonist activity at the P2Y receptor is non-reversible versus its endogenous agonist adenosine 5´-diphosphate. Br J Pharmacol. 2023; 181(1):21-35. PMC: 10953389. DOI: 10.1111/bph.16204. View

20.

Liu S, Xue L, Shi X, Sun Z, Zhu Z, Zhang X . Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects. Eur J Clin Pharmacol. 2018; 74(6):745-754. DOI: 10.1007/s00228-018-2427-3. View